Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Report from Annual General Meeting 2023 of Embellence Group AB (publ)

Embellence Group AB (publ) held its Annual General Meeting today, Friday 28 April 2023, at the company’s premises at Ryssnäsgatan 8 in Borås. Attorney Eric Ehrencrona from MAQS Advokatbyrå was elected as chairman of the Annual General Meeting.The following main resolutions were resolved upon at the Annual General Meeting: Adoption of the income statement and balance sheet, and allocation of resultThe Annual General Meeting resolved to adopt the income statement and the balance sheet for the company and the group for the financial year 2022 presented to the Annual General Meeting.

BERGENBIO ASA: Notice of Annual General Meeting

Bergen, Norway – 28 April 2023: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 22 May 2022 at 16:00 hours (CEST).   The notice, registration form, power of attorney and proposal from Nomination Committee are attached to this release. The notice will be sent to all registered shareholders and is available on the Company’s website: https://www.bergenbio.com/investors/general-meetings/   All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using the

Correction to 2022 financial statement release

Endomines Finland Plc – Financial Statement Release, 28.4.2023, at 16.00 EET.     In connection with the Group's audited Financial Statements, the company revises the figures in the Group's Consolidated Income Statement and Balance Sheet, published in the FY 2022 Financial Statements Release on 15 February 2023.   The corrections have no effect on the turnover, operational costs, or EBITDA of the financial year 2022. Corrections have no cash flow effect.   +-------------------------------------------------+----------------------------------------------------+----------+

Notice of AGM

EnQuest PLC, 28 April 2023 EnQuest PLC Annual Report and Accounts and Notice of Meeting Following the release of EnQuest's 2022 full year audited results on 5 April 2023 and the publication of the Company's 2022 Annual Report and Accounts ('ARA') on 25 April 2023, the Company is pleased to announce that the 2022 ARA and the Notice of the 2023 Annual General Meeting ('AGM') have today been posted to shareholders. These documents are publicly available on the EnQuest PLC website (www.enquest.com), under the Investors section. In compliance with 9.6.1 of the Listing Rules, the Company

Nordic Mining ASA: New share capital registered

Reference is made to the stock exchange release on 17 April 2023 regarding the issuance of 136,544,091 shares in Nordic Mining ASA (the "Company") under the Subsequent Offering. The new share capital following completion of the Subsequent Offering has today been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is NOK 1,300,938,393.0 divided into 2,168,230,655 shares, each with a par value of NOK 0.60. Oslo, 28 April 2023Nordic Mining ASA Nordic Mining ASA (www.nordicmining.com) Nordic Mining ASA (“Nordic Mining” or the “Company”

Swedavia is developing Cargo City at Arlanda - a new center for air cargo and logistics

Stockholm Arlanda Airport is currently in a development phase. Cargo City, a new centre for air cargo, logistics and manufacturing, is being developed in an area close to the terminals, with land for development there covering a total of 144,400 m[2]. Swedavia is looking for one or more partners for a long-term joint venture. Construction is in full swing at Stockholm Arlanda Airport. In the summer of 2023, a new security checkpoint will open in Terminal 5, and in the autumn the first step of new Marketplace will open – the largest commercial investment ever at Arlanda. But

BioStock article: Aptahem on the need for more effective sepsis treatments

Biotechnology company Aptahem is developing Apta-1, a drug candidate whose purpose is to reduce the high mortality and severe tissue damage that can occur in sepsis. BioStock contacted Luiza Jedlina, Chief Scientific Officer and co-founder of Aptahem, to talk about the need for better treatment options than antibiotics.Read the full interview with Luiza Jedlina at biostock.se: https://www.biostock.se/en/2023/04/aptahem-on-the-need-for-more-effective-sepsis-treatments/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com

DexTech Medical AB Interim report July 1, 2022 - March 31, 2023

Summary of the third quarter (2023-01-01 – 2023-03-31) · Patient recruitment has begun for the Multiple Myeloma study · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,6 (-1,1) · Earnings per share* SEK -0.08 (-0.06) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. Summary of the nine-month period (2022-07-01 – 2023-03-31) ·

Change in the number of shares and votes in Starbreeze AB

In accordance with Starbreeze’ articles of association, holders of series A-shares have the right to request that the shares be converted into series B-shares. Such a conversion reduces the total number of votes in the company. When such conversion has taken place, the company has an obligation according to law to publish information about any changes on a monthly basis.During the current month, at the request of shareholder’s, 552,195 shares of series A-shares have been converted into the same number of series B-shares. The total number of votes in Starbreeze then amounts to 2,203,386,648.

Arranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeutics

· Contract with MIT follows the largest award from FDA’s Center for Biologics Evaluation and Research office (CBER) to MIT · Potential to support better response to new pandemic threatsArranta Bio, part of Recipharm’s biologics business, has signed a contract with MIT to develop a continuous manufacturing technology for mRNA therapeutics. The contract is part of the FDA’s initiative to have a fully integrated, continuous manufacturing production line for mRNA vaccines, which the agency is funding through a contract to MIT – one of the largest awards from the FDA’s CBER office. Enabling

BioStock: Aptahem on the need for more effective sepsis treatments

Biotechnology company Aptahem is developing Apta-1, a drug candidate whose purpose is to reduce the high mortality and severe tissue damage that can occur in sepsis. BioStock contacted Luiza Jedlina, Chief Scientific Officer and co-founder of Aptahem, to talk about the need for better treatment options than antibiotics.Read the full interview with Luiza Jedlina at biostock.se: https://www.biostock.se/en/2023/04/aptahem-on-the-need-for-more-effective-sepsis-treatments/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

RugVista Group AB (publ) invitation to Rugvista’s Capital Markets Day

Rugvista welcomes investors, analysts, and financial media to a Capital Markets Day on May 25th, 2023. The Capital Markets Day will be held at our premises at Frihamnsallén 10, Malmö, with the possibility to participate digitally. Together with additional members of the company's management team, CEO Michael Lindskog will provide an update on Rugvista's current development and focus areas. Agenda for the day: Subject PresenterPresentation of Rugvista's vision, long-term Michael Lindskog, CEOstrategy, and ongoing initiatives

OrderYOYO announces capital increase, total share capital and voting rights

Company Announcement No. 52 - 2023 OrderYOYO A/SCompany announcement   Copenhagen, April 28, 2023 Capital increase, total share capital and voting rights of OrderYOYO A/S (“OrderYOYO”) With reference to company announcement no. 51 of April 17, 2023, closing of the share-for-share exchange and acquisition of shares in Kingfood has been completed. Payment to the sellers of Kingfood consists of 1,661,852 new shares in OrderYOYO and DKK 4.5m in cash. The transaction values the total share capital of Kingfood at DKK 13.4m. OrderYOYO therefore announces a directed issue of 1,

Navamedic ASA: Annual Report for 2022

Oslo, 28 April 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, announce that the company has published its Annual Report for 2022, which was approved by the Board of Directors on 27 April 2023.The report is attached to this notice and is available at navamedic.com/investors. In addition, the company has published its annual financial statements in European Single Electronic Format (ESEF).   “The year 2022 can be summarised by Navamedic successfully delivering on its growth ambition through both

SmartCraft ASA (SMCRT) re-initiates share buy-back programme

SmartCraft ASA | Additional regulated information required to be disclosed under the laws of a member state In a stock exchange announcement of 2 November 2022, SmartCraft ASA (the "Company") (Ticker: SMCRT NO) notified the initiation of a share buy-back programme to a maximum of 2% the share capital of the Company (3,430,446 shares). The buy-back programme was conducted in accordance with the authorization granted to the board of directors by the Company's Extraordinary General Meeting held on 2 November 2022. In the period 3 November 2022 to 27 April 2023 the Company purchased a total

Invitation to media and analyst briefing for BioGaia Q1 2023 report

BioGaia's (NASDAQ: BIOG) financial report for the first quarter of 2023 will be published at approximately 8:00 AM CEST on May 5, 2023. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website . CEO Isabelle Ducellier and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST. To join the audiocast with teleconference and ask a

Citycon to publish its Interim Report for January-March 2023 on Thursday, 4 May 2023 after market close

CITYCON OYJ   Investor News   28 April 2023 at 14:00 hrsCitycon will publish its Interim Report for 1 January – 31 March 2023 on Thursday, 4 May 2023 after market close. The report will be available on Citycon’s website immediately after publication.Citycon's investor, analyst and press conference call and live audiocasting will be held on Friday, 5 May 2023 at 10 am EEST. The audiocast can be participated by calling in and following live at this  website: https://citycon.videosync.fi/q1-2023/Questions for the management can be presented by phone. To ask questions, join the

New number of votes in AB Volvo

The number of votes in AB Volvo has changed due to the conversion of a total of 104 Series A shares to a total of 104 Series B shares. The conversions were implemented with the support of the opportunity for Series A shareholders to request conversion of Series A shares to Series B shares which was entered in the Articles of Association at the 2011 Annual General Meeting.Today, 28 April 2023, the last trading day of the month, there are a total of 2,033,452,084 registered shares in AB Volvo. Of these are 444,987,771 Series A shares and 1,588,464,313 Series B shares. The number of votes in

Stendörren publishes Annual and Sustainability Report for 2022

Press release April 28, 2023 The Annual and Sustainability Report for 2022 for Stendörren Fastigheter AB (publ) is now available to download on the company's website www.stendorren.se. For more information, please contact: Erik Ranje, CEO, +46 (0)70-308 52 09, erik.ranje@stendorren.se  or Per-Henrik Karlsson, CFO, +46 (0)72-158 70 92, per-henrik.karlsson@stendorren.se or visit www.stendorren.se This disclosure contains information that Stendörren Fastigheter AB is obligated to make public pursuant to the Swedish Security Markets Act. The information was submitted for

Vasakronan’s Interim Report January–March 2023

Stable results and increased rental revenue· Rental revenue increased 17% (5) to a total of SEK 2,221 million (1,902). In comparable property holdings, the increase in rental revenue was 14% (3). The increase was primarily due to completed projects and indexing. · New lettings were contracted corresponding to 23,000 square metres (44,000) and an annual rent of SEK 121 million (260). Net lettings amounted to a negative SEK 46 million (positive: 125) for the quarter and SEK 99 million (230) for the rolling 12-month period. · The price change after renegotiations averaged 5% above index (

Veidekke: To build public school and sports facility outside Stockholm

Veidekke's subsidiary Arcona has been commissioned by Botkyrka Municipality to build a new school and sports facility in Hallunda outside Stockholm. The design and build contract comprises a total area of 13,500 square meters and is valued at approx. SEK 533 million. Work on the project will start in April 2023 and is scheduled for completion in summer 2025.The new Eleonoraskolan will cater for a total of 915 pre-school to ninth grade students, and will consist of two independent buildings connected by a canopy. A separate sports facility will house school and club sports activities and a

Change in the total number of shares and votes in Sivers Semiconductors AB (publ)

As of 28 April 2023, the total number of shares and votes in Sivers Semiconductors AB (the “Company”) amounts to 234,649,894, divided into 233,549,894 ordinary shares and 1,100,000 shares of series C. The total number of votes in the Company amounts to 233,659,894.The number of shares and votes in the Company has increased as a result of the directed share issue of 20,695,650 ordinary shares resolved by the Board of Directors of the Company on 4 April 2023.  For more information please contact:Anders Storm, CEOTel: +46 70 262 6390E-mail: anders.storm@sivers-semiconductors.com

BERGENBIO ASA: Board approval of 2022 Annual Financial Statement and Annual Report 2022

Bergen, Norway – 28 April 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2022 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS).   The Annual Report for 2022 in pdf and European Single Electronic Format (ESEF) are attached to this release and are also available on BerGenBio ASA's website https://www.bergenbio.com/investors/reports/     Contacts: For

There are no items matching the current filter
There are no more items matching the current filter
Back to top